Arbutus Biopharma
ABUS
#6500
Rank
A$1.24 B
Marketcap
A$6.32
Share price
-2.10%
Change (1 day)
31.99%
Change (1 year)

Revenue for Arbutus Biopharma (ABUS)

Revenue in 2026 (TTM): A$0.27 Billion

According to Arbutus Biopharma 's latest financial reports the company's current revenue (TTM ) is A$0.27 Billion. In 2025 the company made a revenue of A$21.02 Million an increase over the revenue in the year 2024 that were of A$9.92 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Arbutus Biopharma from 2008 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) A$0.27 B1219.95%
2025 A$21.02 M111.93%
2024 A$9.92 M-62.74%
2023 A$26.62 M-53.56%
2022 A$57.33 M278.31%
2021 A$15.15 M68.56%
2020 A$8.99 M4.73%
2019 A$8.58 M1.74%
2018 A$8.43 M-38.43%
2017 A$13.7 M562.6%
2016 A$2.06 M-93.94%
2015 A$34.14 M86.87%
2014 A$18.27 M5.3%
2013 A$17.35 M28.68%
2012 A$13.48 M-18.14%
2011 A$16.47 M-21.56%
2010 A$21 M44.17%
2009 A$14.56 M5.01%
2008 A$13.87 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Nymox Pharmaceutical
NYMX
N/AN/A Bahamas
NRC Health
NRC
A$0.19 B-27.58%๐Ÿ‡บ๐Ÿ‡ธ USA